Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

US Patent 7432268 · Granted Oct 7, 2008

Estimated economic value: $77,394,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

System integration using an abstraction layer2025
Covalent inhibitors of KRAS G12C2025
Heterocyclic compounds and uses thereof2025
Substituted quinazoline compounds and methods of use thereof2025
Method and system for content-based indexing of data streams in streaming storag2025
Heterocyclic compounds and uses thereof2025
Substituted piperazines as inhibitors of KRAS G12C2025
Heterocyclic compounds and uses thereof2025
Macrocyclic heterocycles and uses thereof2025
Generating model training data from a domain specification2024
Heterocyclic spiro compounds and methods of use thereof for the treatment of can2024
Method and system for identifying, managing, and monitoring data dependencies2024